Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis
Real-world observational studies complement open label extensions of clinical trials, often by having a more representative cohort and more complete follow-up. Our data suggest that while serious infections are rare in people on ocrelizumab, non-serious infections become increasingly burdensome. We offer practical suggestions on mitigating the risk of infection on ocrelizumab and other anti-CD20 medications.
Authors
- Emma Tallantyre (ORCID: https://orcid.org/0000-0002-3760-6634)
- Stephen Jolles (ORCID: https://orcid.org/0000-0002-7394-6804)
- Laura Davies
- William J. Watkins (ORCID: https://orcid.org/0000-0003-3262-6588)
- Neil P. Robertson (ORCID: https://orcid.org/0000-0002-5409-4909)
- Rasheed Shehadeh
Institutions
- University Hospital of Wales (GB)
- Cardiff University (GB)
Publication Details
- Journal
- Journal of Neurology
- Published
- 2025-05-22
- DOI
- https://doi.org/10.1007/s00415-025-13133-w
- Citations
- 7
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 10.30